摘要
目的:观察依达拉奉对急性脑梗死患者血清超氧化物歧化酶(SOD)、丙二醛(MDA)水平的影响及治疗效果。方法:选择急性脑梗死患者60例,随机分为治疗组与对照组,对照组用常规治疗方法(血塞通、ASP、胞二磷胆碱等治疗),治疗组在常规治疗的基础上加用依达拉奉治疗14d。两组分别于治疗前和治疗后7、14、21天检测SOD、MDA水平。并对患者进行欧洲脑卒中评分(ESS)疗效评定。结果:治疗前两组血清SOD和MDA水平无明显差异(P>0.05)。经治疗两组血清SOD水平明显高于治疗前(P<0.05),血清MDA水平低于治疗前(P<0.05)。治疗组血清SOD水平明显高于对照组(P<0.01),血清MDA水平明显低于对照组(P<0.01)。两组治疗后7、14、21天ESS比较差异有显著性。结论:依达拉奉可清除脑缺血产生的过多自由基,抑制脂质过氧化反应,减轻脑缺血及再灌注的损伤,起到保护神经细胞的作用,改善脑梗死的预后。
Objective ： To explore the influence of edaravone on the serum levels of SOD and MDA in patients with acute cerebral infarction and therapeutic efficacy. Methods：Sixty cases with acute cerebral infarction were divided randomly into control group and treatment group. Two groups were given routine treatment. The treatment group was added edaravone for 14 days. The serum levels of SOD and MDA were measured before treatment and 7d, 14d and 21d after treatment. Therapeutic efficacy was evaluated by The European Stroke Scale （ESS）. Results：The serum level of SOD and MDA in the treatment group and the control group had no significant difference before treatment （ P 〉 0. 05 ）. The serum level of SOD in two group was significantly higher after treatment （ P 〈 0. 05 ） but the serum level of MDA was lower than that before treatment （ P 〈 0. 05 ）. After treatment the serum levels of SOD in the treatment group was much higher than that in control group （ P 〈 0.01 ） but the serum levels of MDA in the treatment group was much lower than that in control group （P 〈 0.01 ） . ESS of the treatment group and control group at 7d, 14d and 21d had significant differences. Conclusion： Edaravone can effectively scavenge the free radicals of ischemic brain cells, inhibit lipid peroxidation, protect neurocytes and improve the prognosis of patients with acute cerebral infarction.
出处
《沈阳医学院学报》
2008年第1期27-29,共3页
Journal of Shenyang Medical College
